On March 25, LivaNova received FDA approval for its aura6000 system to treat Obstructive Sleep Apnea (OSA). The system utilizes neurostimulation technology and represents a pivotal growth step for the company. The approval was granted based on strong results from clinical trials.
Medtronic (MDT) has received FDA 510(k) clearance for its Stealth AXiS surgical system, expanding its application to include cranial and ear, nose, and throat (ENT) procedures. This regulatory expansion follows a previous clearance for spine procedures, significantly broadening the system's clinical utility. The…
Read the full storyPulse Biosciences (PLSE) has announced a strategic shift to accelerate the development of its nPulse system for treating Atrial Fibrillation (AFib). This decision follows breakthrough clinical data that demonstrated the effectiveness of the system in recent trials, bolstering the company's confidence in its…
Vivos Therapeutics has announced that its supported professional practices have secured "In-Network" status with multiple commercial health insurers and Medicare in the Nevada market. This strategic milestone is designed to facilitate easier patient access to the company’s proprietary sleep apnea treatments by…
LivaNova (LIVN) has officially received approval from the U.S. Food and Drug Administration (FDA) for its innovative aura6000 system. This medical device is designed to treat Obstructive Sleep Apnea (OSA) utilizing advanced neurostimulation technology. The regulatory milestone follows a series of successful clinical…